ImmunityBio has resubmitted its supplemental biologics license application to the U.S. Food and Drug Administration for ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guerin for BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors, after the agency requested updated long-term efficacy data in March 2026. The resubmission follows a regulatory exchange that began in January […]
Insilico Medicine and TaiGen advance AI-designed anemia drug ISM4808 into Phase I trials. Discover what this means for CKD therapy and AI drug discovery.
BD secures EU CE Mark for the Revello vascular covered stent for iliac artery disease. Explore what this device could change for PAD treatment in Europe.
Lohman Technologies and Salvo Health expand their partnership to deploy HomECG+ monitoring in GI care. Discover why HRV data may reshape digital chronic care.
Servier plans a $2.5B acquisition of Day One Biopharmaceuticals to expand its rare oncology pipeline. Discover what the deal means for pediatric glioma.
CHMP backs CAMCEVI 21 mg for advanced prostate cancer in the EU. Discover what the decision means for androgen deprivation therapy and oncology markets.
Revalesio presents new RNS60 stroke data showing reduced brain tissue loss and shorter hospital stays. Discover what this could mean for stroke drug development.
